Franklin Street Properties Corp. Supplemental Operating & Financial Data 401 Edgewater Place ~Wakefield, MA 01880 781.557.1300.~ www.fspreit.com Fourth Quarter 2025 Table of Contents | ` | Pa | Pa | ge | ge | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | - ...

Priority Technology Holdings, Inc. (Nasdaq: PRTH) R: 0 G: 62 B: 41 R: 1 G: 39 B: 26 R: 254 G: 109 B: 18 R: 255 G: 255 B: 255 R: 231 G: 229 B: 170 Supplemental Slides Q4 2025 Earnings Call R: 166 G: 166 B: 166 R: 117 G: 209 B: 208 March 2026 R: 131 G: 201 B: 126 R: 37 G: 37 B: 37 Disclaimer Important Notice Regarding Forward-Looking Statements and Non-GAAP Measures This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statemen ...

Centessa Pharmaceuticals (NasdaqGS:CNTA) 2026 Conference March 10, 2026 08:00 AM ET Speaker0 All right, we'll get started in just one moment here. My name is Dave Risinger. It's very much my pleasure to welcome Centessa to participate in the session today at the Leerink Partners Global Healthcare Conference. I'm very pleased to welcome and introduce Mario Alberto Accardi, who is the company's CEO, and very much looking forward to the discussion. Mario, could you kick us off with some high-level remarks on h ...

Results Q4 2025 & Full year March 10, 2026 Disclaimer Any estimates and statements that may be made during this presentation about future operations regarding our strategy and future growth opportunities are based primarily on our current expectations and estimates or projections of future events and trends that affect or may affect our business and results of operations. Although we believe that these estimates and statements about future operations are based on reasonable assumptions, they are subject to ...

Speaker0 ABS Speaker1 ... ultrasound. Right, ultrasound and interventional therapies, as well as Carolynne Borders. My name is Matt Miksic. I cover U.S. medical devices here at Barclays. First question, I guess, has been kind of thrown into our basket, about a week, a little over a week ago, is a couple of questions around the Middle East and price of oil. You know, one of the things I suspect we'll be asking everyone today and tomorrow is exposure of your business to Middle East to start, and then we'll ge ...

Q4 Results Presentation March 10, 2026 1 Cautionary Statement Regarding Forward-Looking Information This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions to identify forward-looking statements. Forward-looking statements include, but are not limited to, the information under "2026 O ...

Summary of Insmed Conference Call Company Overview - **Company**: Insmed (NasdaqGS:INSM) - **Focus**: Development of treatments for serious, life-threatening conditions, particularly in respiratory diseases - **Commercial Products**: - **ARIKAYCE**: Approved for nontuberculous mycobacteria (NTM) in refractory settings, with a potential label expansion readout expected in March-April 2026 - **BRINSUPRI**: Launched in August 2025 for bronchiectasis, showing strong demand and initial success [2][3][20] Key Points on ARIKAYCE - **ENCORE Study**: A 12-month study designed to assess the primary endpoint of patient-reported outcomes (PRO) and culture conversion rates - **ARISE Study**: A smaller, shorter study that provided preliminary data, showing a 4.5-point change in respiratory symptom scores and an 80% culture conversion rate in the drug arm at the 6-month endpoint [5][6][8][9] - **Patient Population**: Approximately 12,000-17,000 diagnosed patients in the U.S. and 15,000-18,000 in Japan under the current label, with total NTM cases estimated at 100,000 in the U.S. and 125,000 in Japan [11] - **Potential Outcomes**: - Clear win scenario: Filing for market approval by the end of 2026 - Mixed results: Discussion with FDA regarding the product's continued availability due to its established patient impact [14][18][19] Key Points on BRINSUPRI - **Market Potential**: First and only treatment for bronchiectasis, with an estimated 500,000 diagnosed patients in the U.S. - **Initial Focus**: Targeting patients with two or more exacerbations in the past 12 months, estimated at 250,000 patients, with potential for an additional 250,000 patients who may be under-diagnosed [25][26][28] - **Launch Strategy**: A secondary focus on under-diagnosed patients with COPD or asthma, with a potential overlap of 30%-50% of moderate to severe COPD patients also having bronchiectasis [29][30] - **Revenue Goals**: Aiming for at least $1 billion in revenue for the year, with peak sales potential estimated at $5 billion [39] Other Important Developments - **TPIP**: A new prostacyclin therapy showing promising results in phase 2 studies, with a potential peak sales estimate of $2 billion. Four global phase 3 programs are planned to commence [44][46][47] - **INS1033**: A next-generation DPP1 therapy targeting rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), expected to progress through IND by the end of the year [53][54] - **INS1148**: A monoclonal antibody recently acquired for ILD and asthma, showing promise in previous studies and expected to enter clinical trials soon [55][56] Conclusion Insmed is positioned for significant growth with its innovative therapies targeting serious respiratory conditions. The upcoming data readouts and market strategies for ARIKAYCE and BRINSUPRI are critical for the company's future success, alongside the development of new therapies like TPIP and INS1033.

Custom Truck One Source 4th Quarter 2025 Investor Presentation March 10, 2026 CONFIDENTIAL DRAFT1 Safe Harbor This presentation includes certain financial measures that have not been prepared in a manner that complies with generally accepted accounting principles in the United States ("GAAP"), including, without limitation, Adjusted Gross Profit, Adjusted Gross Margin, EBITDA and Adjusted EBITDA (collectively, the "non-GAAP financial measures"). These non-GAAP financial measures may exclude items that are s ...

First Quarter 2026 Earnings Presentation March 10, 2026 Forward Looking Statements This press release contains both historical and forward-looking statements about ABM Industries Incorporated ("ABM") and its subsidiaries (collectively referred to as "ABM," "we," "us," "our," or the "Company"). We make forward-looking statements related to future expectations, estimates and projections that are uncertain, and often contain words such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "int ...

2nd Quarter Fiscal 2026 March 10, 2026 Disclaimer Certain information in this presentation and discussed on the conference call which this presentation accompanies constitutes forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this presentation regarding the Company's business that are not historical facts are "forward-looking statements" that involve risks and uncertainties and are based on current expectations and management estimates; act ...